New Results Healthcare Report Examines CRO Market M&A Drivers and Trends
![](/46/pdcnewsitem/03/27/78/jeRv0dSl17uRGyq.png)
“CROs and other outsourced pharmaceutical support services — M&A drivers and trends” is the title of a new report by healthcare sector corporate finance and strategy specialist, Results Healthcare.
The report examines the rationale for the M&A activity that has been rife across the contract research organisation (CRO) sector and provides Results Healthcare’s view on where future M&A activity is likely to be focused. As well as providing a background on the current and foreseeable market climate, the report looks beyond CRO players to other outsourced support services providers and examines the M&A trends for specialists providing site management organisation (SMO) services, as well as market access, pharmacovigilance and e-clinical solutions. It provides an overview of a selection of key deals completed in the past few years and further highlights the future prospects of this dynamic, developing and growing market.
The CRO sector is seeing a recovery, driven by improved optimism across the biopharma industry, the sector’s largest customer group, where many key CRO customers are now at the tail end of multi-year patent cliffs and are stepping up investments into their pipelines, particularly products in late-stage development. After 2 years of declining budgets, rising R&D expenditure and increased outsourcing, due primarily to biopharma’s need to shift fixed to variable costs and access capabilities not found internally, are expected to continue fuelling steady growth of the global CRO market. As such, the market is poised to grow from $23–25 billion today to more than $30 billion by 2018, according to recent estimates from Bank of America Merrill Lynch, reflecting a 5–6% CAGR, led by faster growth of late-stage versus early development services.
The report observes that although M&A continues to be driven primarily by strategic buyers looking to increase scale or add specialist capabilities they lack in-house to improve their overall service offering, it is often the private equity deals that make the headlines, frequently because of their sheer scale and the impact they have on the industry. It cites two important secondary private equity transactions completed this year, KKR’s purchase of PRA International and Research Pharmaceutical Services (RPS), as evidence of consolidation and a move to increase scale, and potentially game changing deals in the CRO sector.
“We are seeing strong appetites for acquisition in particular segments of the CRO sector,” commented Hemavli Bali, Executive Director, Results Healthcare. “These range from medical communications and patient recruitment, to health economics and outcomes research, to patient engagement solutions, health informatics and pharmacovigilance. Healthcare IT will also remain a major focus, as CROs look to increase efficiencies across the board, including technologies that allow for real-time access to data, cloud platforms, and the use of mobile devices to simplify the collection of data.”
The full report is available to download free of charge at www.resultshealthcare.com/news-insights/white-papers/cro-white-paper
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance